Navigation Links
Webcast Alert: Isis Pharmaceuticals' Third Quarter 2013 Financial Results Conference Call
Date:10/29/2013

CARLSBAD, Calif., Oct. 29, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announces the following webcast:What:

Isis Pharmaceuticals' Third Quarter 2013 Financial Results and Highlights Conference CallWhen:

Tuesday, November 5, 2013 at 11:30 a.m. ET / 8:30 a.m. PTWhere:

www.isispharm.comHow:

Live on the Internet.  Simply log onto our website listed above. If you are unable to participate during the live event, a replay of the webcast will be available for a limited time at www.isispharm.com.

ABOUT ISIS PHARMACEUTICALS, INC.Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 30 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, including neurological disorders, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENTThis press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, and its most recent quarterly report on Form 10-Q, which are on file with the SEC. Copies of these and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.

(Logo:  http://photos.prnewswire.com/prnh/20130807/LA60006LOGO)


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Webcast Alert: Heska Announces Third Quarter 2013 Earnings Conference Call Webcast
2. InRetail Peru to Host Third Quarter 2013 Earnings Conference Call & Audio Webcast
3. Neurocrine Biosciences Announces Conference Call And Webcast To Present Third Quarter 2013 Financial Results
4. AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference Call and Webcast on November 5, 2013
5. Hill-Rom Holdings, Inc. Hosts Fiscal 2013 Fourth Quarter Earnings Conference Call and Webcast
6. BD Announces Live Webcast Of Fourth Fiscal Quarter Earnings Conference Call
7. Actavis, Inc. to Host Third Quarter 2013 Earnings Conference Call and Webcast
8. Isis Pharmaceuticals to Conduct Webcast and Conference Call to Discuss ISIS-APOCIII Rx Phase 2 Data
9. Pro-Dex, Inc. Announces Fiscal 2013 Fourth Quarter And Full-Year Financial Results Conference Call And Webcast
10. Bone Biologics to Webcast, Live, at RetailInvestorConferences.com on September 12th
11. Thoratec Presentation At Morgan Stanley 2013 Health Care Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... WOONSOCKET, R.I. , Dec. 2, 2016 ... hold its annual Analyst Day in New York City on Thursday, December ... the CVS Health leadership team will provide an in-depth ... and enhance shareholder value. The company will also discuss ... audio and video webcast of the event will be ...
(Date:12/2/2016)... 2, 2016 Orthopedic Implants (Including Spinal ... Expected to Gain a Significant Market Share Owing to a ... ... According to a new report by ... Sterile Packaging: Clamshell Product Type Segment Projected to Witness a ...
(Date:12/2/2016)... N.J. , Dec. 2, 2016   CytoSorbents ... immunotherapy leader commercializing its European Union approved CytoSorb ... and cardiac surgery patients worldwide, announced that Dr. ... the 9th Annual LD Micro Main Event ... , 2016 at the Luxe Sunset Boulevard Hotel in ...
Breaking Medicine Technology:
(Date:12/2/2016)... ... , ... Mediaplanet is proud to announce the launch of ... treatments, therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage ... in the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This ...
(Date:12/2/2016)... ... , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a unique wearable technology ... health technology on the market can deliver all that rejiva can. , “Rejiva promotes ... their health than the usual heart rate and steps taken”, adds Evens Augustin, CEO ...
(Date:12/2/2016)... ... December 02, 2016 , ... Today ... intelligent, connected applications, was named the best Sales Team of 2016 as part ... was made today by the Software & Information Industry Association (SIIA), the principal ...
(Date:11/30/2016)... ... , ... "I hate when the mixture of saliva and toothpaste runs down ... from Bridgewater, N.J. "I thought that there had to be a way to prevent ... patent-pending DEFLECTOR to prevent saliva and toothpaste from running down the brush handle onto ...
(Date:11/30/2016)... U.K. (PRWEB) , ... November 30, 2016 , ... ... address the tech functions and stylish design wanted by today’s consumers at an ... Cronovo Co-Founder Darin Philip says the new watch is “a game changer” when ...
Breaking Medicine News(10 mins):